PRLD Prelude Therapeutics Incorporated
USHealthcareAs of 2026-08-24
Why PRLD matters now
Prelude Therapeutics Incorporated (PRLD) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.47 with -2.41% on the session and $368.4M in market capitalization; recent performance reads 1-month +1.17% and YTD +48.97%.
The latest financial table shown here is Q1 2026, with revenue of $4.6M, net income of $-10.4M, and EPS of $-0.13. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -17.8%.
The latest indexable market news headline is "Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $8.00; recent insider activity includes FRIEDMAN PAUL A filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.92
P/S
14.71
EV/EBITDA
-3.18
DCF Value
$3.87
FCF Yield
-17.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.7%
Operating Margin
-503.2%
Net Margin
-465.3%
ROE
-118.2%
ROA
-65.0%
ROIC
-104.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $4.6M | $-10.4M | $-0.13 |
| Q4 2025 | $5.6M | $-16.5M | $-0.26 |
| FY 2025 | $12.1M | $-99.5M | $-1.29 |
| Q3 2025 | $6.5M | $-19.7M | $-0.26 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$8.00
Target (Median)
$8.00
Target Range
$8.00 - $8.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.01
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.